keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatology;biologics

keyword
https://www.readbyqxmd.com/read/29142041/occurrence-of-serious-infection-in-patients-with-rheumatoid-arthritis-treated-with-biologics-and-denosumab-observed-in-a-clinical-setting
#1
Arthur N Lau, Matthew Wong-Pack, Rod Rodjanapiches, George Ioannidis, Sally Wade, Leslie Spangler, Akhila Balasubramanian, Nicola Pannacciulli, Celia J F Lin, Patrick Roy-Gayos, William G Bensen, Robert Bensen, Jonathan D Adachi
OBJECTIVE: Previous studies combining biologic disease-modifying antirheumatic drugs (bDMARD) to treat rheumatoid arthritis (RA) have shown an increased risk of infection. However, the risk of infection with concurrent use of denosumab, a biologic agent for the treatment of osteoporosis, and a bDMARD remains unclear. Here, we evaluated the incidence of serious and opportunistic infections in patients treated concurrently with denosumab and a bDMARD and patients treated with a bDMARD alone...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29142040/use-of-disease-modifying-antirheumatic-drugs-for-inflammatory-arthritis-in-us-veterans-effect-of-specialty-care-and-geographic-distance
#2
Jessica A Walsh, Shaobo Pei, Zachary Burningham, Gopi Penmetsa, Grant W Cannon, Daniel O Clegg, Brian C Sauer
OBJECTIVE: To evaluate the effect of access to and distance from rheumatology care on the use of disease-modifying antirheumatic drugs (DMARD) in US veterans with inflammatory arthritis (IA). METHODS: Provider encounters and DMARD dispensations for IA (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) were evaluated in national Veterans Affairs (VA) datasets between January 1, 2015, and December 31, 2015. RESULTS: Among 12,589 veterans with IA, 23...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29142036/effect-of-glucocorticoids-on-the-clinical-and-radiographic-efficacy-of-tofacitinib-in-patients-with-rheumatoid-arthritis-a-posthoc-analysis-of-data-from-6-phase-iii-studies
#3
Christina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, Peter Nash, Cristiano A F Zerbini, Carol A Connell, Haiyun Fan, Kenneth Kwok, Eustratios Bananis, Roy Fleischmann
OBJECTIVE: Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase III studies in which concomitant glucocorticoids (GC) were allowed. We analyzed the effect of GC use on efficacy outcomes in patients with RA receiving tofacitinib and/or methotrexate (MTX) or conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in these studies. METHODS: Our posthoc analysis included data from 6 phase III studies (NCT01039688; NCT00814307; NCT00847613; NCT00853385; NCT00856544; NCT00960440)...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29141677/factors-associated-with-oral-glucocorticoid-use-in-patients-with-rheumatoid-arthritis-a-drug-use-study-from-a-prospective-national-biologics-registry
#4
Rachel J Black, Susan Lester, Rachelle Buchbinder, Claire Barrett, Marissa Lassere, Lyn March, Samuel Whittle, Catherine L Hill
BACKGROUND: Glucocorticoids (GCs) are used in ~ 60% of patients with rheumatoid arthritis (RA). Although disease-modifying, they also have significant adverse effects. Understanding factors associated with GC use may help minimise exposure. The aims of the present study were to describe oral GC use in RA; determine any change in use over time; and determine factors associated with oral GC use, commencement or cessation. METHODS: Adult patients with RA were identified in the Australian Rheumatology Association Database (ARAD), a national Australian registry that collects long-term outcome data from patients with inflammatory arthritis...
November 15, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29138986/secukinumab-in-active-rheumatoid-arthritis-after-anti-tnf%C3%AE-therapy-a-randomized-double-blind-placebo-controlled-phase-3-study
#5
Hasan Tahir, Atul Deodhar, Mark Genovese, Tsutomu Takeuchi, Jacob Aelion, Filip Van den Bosch, Sibylle Haemmerle, Hanno B Richards
INTRODUCTION: 'REASSURE' (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors). METHODS: A total of 637 patients were randomized (1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks (starting from week 8) or placebo at the same dosing schedule...
November 14, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#6
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
November 10, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29116543/remission-assessment-of-rheumatoid-arthritis-in-daily-practice-in-china-a-cross-sectional-observational-study
#7
Huaqun Zhu, Ru Li, Zhanyun Da, Liqi Bi, Xiangpei Li, Yang Li, Chongyang Liu, Fengxiao Zhang, Zhijun Li, Xiangyuan Liu, Zhiyi Zhang, Lingyun Sun, Youlian Wang, Wei Zhang, Quan Jiang, Jinwei Chen, Qingping Chen, Zhenbin Li, Lijun Wu, Wencheng Qi, Jianhua Xu, Xiangjun Cui, Xiaofei Wang, Long Li, Xiaomei Leng, Guochun Wang, Dongbao Zhao, Lindi Jiang, Dongyi He, Xiaomin Liu, Ling Li, Yongfei Fang, Cibo Huang, Huaxiang Wu, Shaoxian Hu, Qin Li, Hui Song, Weiguo Xiao, Lu Gong, Liaojia Zhang, Xiaofeng Li, Zhanguo Li, Yin Su
The objective of this study is to evaluate the remission rate and describe the current use of medication in a large cohort of rheumatoid arthritis (RA) patients under routine clinical care in China. RA patients were recruited from 40 large teaching hospitals nationwide in China. Data regarding RA disease activity, medication treatment, and adverse events were recorded using a standardized clinical data questionnaire. RA remission was evaluated by the 28 Joint Disease Activity Score DAS28-ESR Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria...
November 7, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29116003/protocols-on-classification-monitoring-and-therapy-in-children-s-rheumatology-pro-kind-results-of-the-working-group-polyarticular-juvenile-idiopathic-arthritis
#8
REVIEW
Gerd Horneff, Ariane Klein, Gerd Ganser, Michaela Sailer-Höck, Annette Günther, Ivan Foeldvari, Frank Weller-Heinemann
OBJECTIVE: Several effective pharmacologic treatment options for polyarticual juvenile idiopathic arthritis (JIA) have emerged but initial treatment is heterogeneous in Germany. Therefore, the German Society of Pediatric Rheumatolgy has established a commission to develop consensus "Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND)" to harmonize diagnostic and treatment approaches for new-onset JIA in Germany. METHODS: A set of definitions for in- and exclusion, diagnostic workup, parameters for the evaluation of disease activity criteria, therapeutic options, medication dosing, monitoring recommendations, targets, definitions of a therapy failure and four therapeutic algorithms developed by a working group were agreed by web based survey to which all members of the GKJR have been invited...
November 7, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/29111261/recommendations-of-the-spanish-society-of-rheumatology-on-treatment-and-use-of-systemic-biological-and-non-biological-therapies-in-psoriatic-arthritis
#9
Juan Carlos Torre Alonso, Petra Díaz Del Campo Fontecha, Raquel Almodóvar, Juan D Cañete, Carlos Montilla Morales, Mireia Moreno, Chamaida Plasencia-Rodríguez, Julio Ramírez García, Rubén Queiro
OBJECTIVE: The main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panelists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimization of treatment. METHODS: The recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call...
October 27, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29097373/predictors-of-revision-prosthetic-joint-infection-and-mortality-following-total-hip-or-total-knee-arthroplasty-in-patients-with-rheumatoid-arthritis-a-nationwide-cohort-study-using-danish-healthcare-registers
#10
Rene Lindholm Cordtz, Kristian Zobbe, Pil Højgaard, Lars Erik Kristensen, Søren Overgaard, Anders Odgaard, Hanne Lindegaard, Lene Dreyer
OBJECTIVES: To investigate predictors of 10-year risk of revision and 1-year risk of prosthetic joint infection (PJI) and death following total hip/total knee arthroplasty (THA/TKA) in (1) patients with rheumatoid arthritis (RA) compared with patients with osteoarthritis (OA); and (2) patients with RA treated with biological disease-modifying antirheumatic drugs (bDMARD) within 90 days preceding surgery compared with non-treated. METHODS: Register-based cohort study using the Danish National Patient Register, the DANBIO rheumatology register (RA-specific confounders and treatment episodes) and the Danish Hip and Knee Arthroplasty Registers...
November 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29080437/nursing-sensitive-outcomes-in-patients-with-rheumatoid-arthritis-a-systematic-literature-review
#11
Patricia Minnock, Gabrielle McKee, Alexia Kelly, Sheree C Carter, Victoria Menzies, Denis O'Sullivan, Pam Richards, Mwidimi Ndosi, Yvonne van Eijk Hustings
BACKGROUND: Although rheumatology nursing has been shown to be effective in managing patients with rheumatoid arthritis, patient outcomes sensitive to nursing interventions (nursing sensitive outcomes) have not been systematically studied. OBJECTIVES: The objective of this study was to identify and delineate relevant patient outcomes measured in studies that reported nursing interventions in patients with rheumatoid arthritis. DESIGN: A systematic search was conducted from 1990 to 2016...
September 12, 2017: International Journal of Nursing Studies
https://www.readbyqxmd.com/read/29069471/serious-infusion-related-reaction-after-rituximab-abatacept-and-tocilizumab-in-rheumatoid-arthritis-prospective-registry-data
#12
Jean-Hugues Salmon, Jeanne-Marie Perotin, Jacques Morel, Moustapha Dramé, Alain Cantagrel, Liana Euller Ziegler, Philippe Ravaud, Jean Sibilia, Isabelle Pane, Xavier Mariette, Jacques-Eric Gottenberg
Objective: The aim was to evaluate the incidence of serious infusion-related reactions (SIRRs) in RA treated by non-TNF-targeted biologics. Methods: We analysed data from three independent prospective registers, namely autoimmunity and rituximab, Orencia (abatacept) and RA (ORA) and Registry RoAcTEmra (tocilizumab), promoted by the French Society of Rheumatology and including patients with RA. SIRRs were defined by an occurrence during or within 24 h of an infusion and requiring discontinuation of treatment...
October 23, 2017: Rheumatology
https://www.readbyqxmd.com/read/29065901/predictive-biological-markers-of-systemic-lupus-erythematosus-flares-a-systematic-literature-review
#13
Noémie Gensous, Aurélie Marti, Thomas Barnetche, Patrick Blanco, Estibaliz Lazaro, Julien Seneschal, Marie-Elise Truchetet, Pierre Duffau, Christophe Richez
BACKGROUND: The aim of this study was to identify the most reliable biomarkers in the literature that could be used as flare predictors in systemic lupus erythematosus (SLE). METHODS: A systematic review of the literature was performed using two databases (MEDLINE and EMBASE) through April 2015 and congress abstracts from the American College of Rheumatology and the European League Against Rheumatism were reviewed from 2010 to 2014. Two independent reviewers screened titles and abstracts and analysed selected papers in detail, using a specific questionnaire...
October 24, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29050839/recommendations-by-the-spanish-society-of-rheumatology-on-the-use-of-biological-therapies-in-axial-spondyloarthritis
#14
Jordi Gratacós, Petra Díaz Del Campo Fontecha, Cristina Fernández-Carballido, Xavier Juanola Roura, Luis Francisco Linares Ferrando, Eugenio de Miguel Mendieta, Santiago Muñoz Fernández, Jose Luis Rosales-Alexander, Pedro Zarco Montejo, Mercedes Guerra Rodríguez, Victoria Navarro Compán
OBJECTIVE: Recent data published on biological therapy in axial spondyloarthritis (axSpA) since the last publication of the recommendations of the Spanish Society of Rheumatology (SER) has led to the generation of a review of these recommendations based on the best possible evidence. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with axSpA. METHODS: Recommendations were drawn up following a nominal group methodology and based on systematic reviews...
October 16, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29042750/current-perspective-on-rituximab-in-rheumatic-diseases
#15
REVIEW
Tommaso Schioppo, Francesca Ingegnoli
The steadily increasing knowledge regarding pathogenetic mechanisms in autoimmune rheumatic diseases has paved the way to different therapeutic approaches. In particular, the market entry of biologics has dramatically modified the natural history of rheumatic chronic inflammatory diseases with a meaningful impact on patients' quality of life. Among the wide spectrum of available biological treatments, rituximab (RTX), first used in the treatment of non-Hodgkin's lymphoma, was later approved for rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29032909/subclinical-synovitis-measured-by-ultrasound-in-rheumatoid-arthritis-patients-with-clinical-remission-induced-by-synthetic-and-biological-modifying-disease-drugs
#16
Marcos Cruces, Soham Al Snih, Natalí Serra-Bonett, Juan C Rivas
BACKGROUND: Rheumatoid arthritis (RA) patients with disease in clinical remission might show subclinical synovitis, which can be related to the progress of structural joint damage. OBJECTIVE: To determine and compare the degree of synovial inflammation by ultrasound (US) in patients with RA in clinical remission, treated with DMARD or combination therapy with DMARD and anti-TNF. METHODS: Hospital-based cross-sectional study of 58 patients with RA in sustained remission for at least 6 months by DAS28 <2...
October 9, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29022134/the-impact-of-smoking-on-disease-activity-disability-and-radiographic-damage-in-rheumatoid-arthritis-is-cigarette-protective
#17
Mario Andrés Quintana-Duque, Federico Rondon-Herrera, Enrique Calvo-Paramo, Juan Jose Yunis, Adriana Varela-Nariño, Antonio Iglesias-Gamarra
The ojective of this study is to assess the effect of tobacco smoking on disease activity, functional ability, and joint damage in a cohort of patients with early onset rheumatoid arthritis (EORA). 129 EORA patients attending the Rheumatology Unit of the School of Medicine of the "Universidad Nacional de Colombia" and the "Clínica de Artritis y Rehabilitación" in Bogota, Colombia, were enrolled in a prospective observational cohort study with 3-year follow-up. Clinical, biological, immunogenetics, and radiographic data were analyzed...
December 2017: Rheumatology International
https://www.readbyqxmd.com/read/28983775/deficiency-of-adenosine-deaminase-2-dada2-an-inherited-cause-of-polyarteritis-nodosa-and-a-mimic-of-other-systemic-rheumatologic-disorders
#18
REVIEW
Hasan Hashem, Susan J Kelly, Nancy J Ganson, Michael S Hershfield
PURPOSE OF REVIEW: A new autoinflammatory disease, deficiency of adenosine deaminase 2 (DADA2), caused by mutations in the CECR1 gene, was first reported in 2014. This review aims to update progress in defining, treating, and understanding this multi-faceted disorder. RECENT FINDINGS: DADA2 was first described in patients with systemic inflammation, mild immune deficiency, and vasculopathy manifested as recurrent stroke or polyarteritis nodosa (PAN). More than 125 patients have now been reported, and the phenotype has expanded to include children and adults presenting primarily with pure red cell aplasia (PRCA), or with antibody deficiency...
October 5, 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28975568/modeled-health-economic-impact-of-a-hypothetical-certolizumab-pegol-risk-sharing-scheme-for-patients-with-moderate-to-severe-rheumatoid-arthritis-in-finland
#19
Erkki Soini, Christian Asseburg, Maarit Taiha, Kari Puolakka, Oana Purcaru, Riitta Luosujärvi
PURPOSE: To model the American College of Rheumatology (ACR) outcomes, cost-effectiveness, and budget impact of certolizumab pegol (CZP) (with and without a hypothetical risk-sharing scheme at treatment initiation for biologic-naïve patients) versus the current mix of reimbursed biologics for treatment of moderate-to-severe rheumatoid arthritis (RA) in Finland. METHODS: A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015-2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence...
October 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28968862/serious-infection-risk-after-1-year-between-patients-with-rheumatoid-arthritis-treated-with-rituximab-or-with-a-second-tnfi-after-initial-tnfi-failure-results-from-the-british-society-for-rheumatology-biologics-register-for-rheumatoid-arthritis
#20
Lucía Silva-Fernández, Diederik De Cock, Mark Lunt, Audrey S Low, Kath D Watson, Deborah P M Symmons, Kimme L Hyrich
Objectives: Both TNF inhibitors (TNFi) and rituximab (RTX), a B-cell depleting biologic, can disrupt the immune system in RA. RTX is licensed in Europe for use following TNFi failure. However, safety data on serious infections (SIs) are scarce for RTX in daily practice. This analysis aims to compare the risk of SIs in the first year after a switch to either TNFi or RTX in patients who have failed a first TNFi. Methods: This study included patients with RA registered with the British Society for Rheumatology Biologics Register (BSRBR-RA) who switched to either a second TNFi or RTX after failing a first TNFi...
August 16, 2017: Rheumatology
keyword
keyword
47772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"